Among the many things columnist Candace Semien had to learn while living with lupus were the types and function of various ...

One year of treatment with dapirolizumab pegol reduced fatigue and disease activity in people with SLE in a Phase 3 trial.

TFAM is a protein critical for maintaining the integrity of mitochondrial DNA, and is among the molecules mitochondria release as a stress signal. But the potential role of TFAM in driving SLE-related ...

Few couples hearing the term “in sickness and in health” at their wedding have thoughts of chronic illness enter their mind. But the reality is, with almost half of the American population dealing ...

The trial, Reversing Autoimmunity through Cell Therapy (REACT-01), is targeted for a summer launch. Seattle Children’s Therapeutics, a nonprofit that’s been running immunotherapy trials for children, ...

If my body contributed to the Job of Living, it was limited to completing and surviving the day’s tasks and soaking in only essential oils and hot water. While I strategically planned to execute the ...

His soulful, smooth voice continues: “Yeah, let yourself go, follow that feeling/ Maybe something new is what you’re needing/ Like a real night, let your hair down, feel alive.” Doing something for ...

This is the first time a blood biomarker has been linked to fatigue in SLE patients. The findings were recently presented at the 11 th European Lupus Meeting in Düsseldorf, Germany, in the study, “ ...

The study, “ VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like disease,” was published in the journal Science. Mitochondria are the small compartments in cells ...

They found that 21.4 to 26 percent more of the children developed learning disorders than children born to mothers without lupus. In addition, 14.3 to 21.6 percent more children born to mothers with ...

Therefore, researchers set out to determine the prevalence of ACE among patients with known SLE compared with the general population, as well as to examine the relationship between ACEs and health ...

Overall, meaningful reduction in disease activity was achieved by 75.8% of patients taking the higher RC18 dose (240 mg), 68.3% of those on the middle dose (160 mg), 71% of patients given the lower ...